Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The Systemic Necrotizing Vasculitides (SNV) encompass a group of rare diseases which include
Wegener's Granulomatosis (WG), Churg-Strauss Syndrome (CSS), Microscopic polyangiitis
(MPA)and Polyarteritis nodosa (PAN). Common histological findings are inflammation with
fibrinoid necrosis of the small vessels and sporadic or absent immune-deposits. The gold
standard therapy for SNV is currently represented by the association of Cyclophosphamide and
Prednisone. The limits of this approach are the high frequency of recurrent disease and an
increased incidence of malignancy and infections. The aim of the present study is to compare
the efficacy of Methotrexate vs Cyclophosphamide for Remission Maintenance in SNV.